MX377257B - Gránulos de monensina dispersables en agua por granulación húmeda. - Google Patents

Gránulos de monensina dispersables en agua por granulación húmeda.

Info

Publication number
MX377257B
MX377257B MX2017013693A MX2017013693A MX377257B MX 377257 B MX377257 B MX 377257B MX 2017013693 A MX2017013693 A MX 2017013693A MX 2017013693 A MX2017013693 A MX 2017013693A MX 377257 B MX377257 B MX 377257B
Authority
MX
Mexico
Prior art keywords
monensin
water
wet granulation
present disclosure
granules dispersible
Prior art date
Application number
MX2017013693A
Other languages
English (en)
Other versions
MX2017013693A (es
Inventor
Constantine Paul Benikos
Edward John Key
John Malcolm Lloyd
Kim Ewing Melville Agnew
William Austin Hewitt
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of MX2017013693A publication Critical patent/MX2017013693A/es
Publication of MX377257B publication Critical patent/MX377257B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención se refiere a una formulación de gránulo dispersable en agua que comprenden desde aproximadamente 5% hasta aproximadamente 80% (p/p) de monensina; desde aproximadamente 1% hasta aproximadamente 20% (p/p) de uno o más surfactantes; desde aproximadamente 1% hasta aproximadamente 30% (p/p) de uno o más aglutinantes; desde aproximadamente 1% hasta aproximadamente 90% (p/p) de uno o más rellenadores; y agua hasta aproximadamente 2% (p/p). La presente descripción también proporciona un proceso para la preparación de formulación de gránulo de monensina dispersable en agua. La presente descripción proporciona, además, un método para administrar una cantidad terapéuticamente efectiva de una formulación de gránulo de monensina dispersable en agua a un animal.
MX2017013693A 2015-04-28 2016-04-22 Gránulos de monensina dispersables en agua por granulación húmeda. MX377257B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153592P 2015-04-28 2015-04-28
PCT/US2016/028932 WO2016176121A1 (en) 2015-04-28 2016-04-22 Monensin water dispersible granules by wet granulation

Publications (2)

Publication Number Publication Date
MX2017013693A MX2017013693A (es) 2018-03-02
MX377257B true MX377257B (es) 2025-03-07

Family

ID=55949105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013693A MX377257B (es) 2015-04-28 2016-04-22 Gránulos de monensina dispersables en agua por granulación húmeda.

Country Status (15)

Country Link
US (1) US10117849B2 (es)
EP (1) EP3288535B1 (es)
JP (1) JP6403242B2 (es)
KR (1) KR102060234B1 (es)
CN (1) CN107530286B (es)
AU (1) AU2016254983B2 (es)
CA (1) CA2978016C (es)
CL (1) CL2017002649A1 (es)
EA (1) EA033344B1 (es)
ES (1) ES2998015T3 (es)
HK (1) HK1245656A1 (es)
MX (1) MX377257B (es)
NZ (1) NZ735038A (es)
WO (1) WO2016176121A1 (es)
ZA (1) ZA201706186B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102019008505A2 (pt) * 2019-04-26 2020-11-03 Mônica Filomena Assis De Souza Composição homeopática para tratamento de animais domésticos, silvestres, peixes, anfíbios e outros
KR20210015545A (ko) 2019-08-02 2021-02-10 주식회사 파인드커넥트 수익공유형 온라인 광고 서비스 시스템

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475375A (en) * 1967-06-23 1969-10-28 Du Pont Novel amorphous guanidine silicates,and compositions thereof with synthetic resins
IL70015A0 (en) 1983-10-20 1984-01-31 Koffolk 1949 Ltd Ionophore antibiotic compositions and processes for the preparation thereof
US5443764A (en) * 1987-07-01 1995-08-22 Ici Australia Operations Propietary Limited Water-dispersible granules
CA2225741C (en) * 1995-07-14 2006-10-03 Eli Lilly & Co (Nz) Limited Ionophore antibiotic formulations
NZ272574A (en) 1995-07-14 1999-02-25 Lilly Eli & Co Nz Ltd Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment
NZ280384A (en) * 1995-11-02 1997-01-29 Lilly Eli & Co Nz Ltd Animal feed supplement comprising a wettable powder composition of an ionophore antibiotic
ATE250419T1 (de) * 1995-11-02 2003-10-15 Eli Lilly & Company Nz Ltd Trockene zusammensetzungen von ionophoren antibiotika
JP4919537B2 (ja) 2000-02-01 2012-04-18 ファロ テクノロジーズ インコーポレーテッド 座標測定システムに実行可能プログラムを提供する方法、システム、および記憶媒体
AU2002216503B9 (en) * 2000-12-19 2006-10-12 Elanco U.S. Inc. Ionophore antibiotic formulations
CN102525880B (zh) * 2010-12-31 2014-06-11 正大天晴药业集团股份有限公司 一种阿瑞匹坦固体分散组合物
NZ596017A (en) 2011-10-26 2014-04-30 Glenmark Ip Ltd Ionophore antibiotic veterinary composition and method of manufacture
KR101473851B1 (ko) * 2013-01-25 2014-12-18 대한뉴팜(주) 모넨신을 주성분으로 하는 가축의 콕시듐증 예방용 펠릿형 조성물 및 그의 제조방법
US9648872B2 (en) * 2014-02-19 2017-05-16 Deepak Pranjivandas Shah Water dispersible granule composition

Also Published As

Publication number Publication date
US20180042888A1 (en) 2018-02-15
ZA201706186B (en) 2020-01-29
MX2017013693A (es) 2018-03-02
CL2017002649A1 (es) 2018-04-20
JP2018515465A (ja) 2018-06-14
JP6403242B2 (ja) 2018-10-10
AU2016254983B2 (en) 2018-07-19
AU2016254983A1 (en) 2017-09-14
CN107530286A (zh) 2018-01-02
US10117849B2 (en) 2018-11-06
HK1245656A1 (zh) 2018-08-31
CA2978016C (en) 2019-11-26
CA2978016A1 (en) 2016-11-03
WO2016176121A1 (en) 2016-11-03
EA201792104A1 (ru) 2018-03-30
KR20170130563A (ko) 2017-11-28
KR102060234B1 (ko) 2019-12-27
BR112017018496A2 (pt) 2018-04-17
NZ735038A (en) 2018-05-25
EP3288535B1 (en) 2024-08-21
ES2998015T3 (en) 2025-02-18
CN107530286B (zh) 2021-11-16
EA033344B1 (ru) 2019-09-30
EP3288535A1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PT3383363T (pt) Formulações farmacêuticas tópicas para o tratamento de afeções relacionadas com inflamações
EP3331360A4 (en) CHOLIN SALT AND AMMONIUM-FREE ADJUVANTIES FOR WATER TREATMENT AND AGRICULTURAL FORMULATIONS
MX384346B (es) Bloqueo de cd73.
DOP2016000195A (es) Compuestos
MX390083B (es) Formulaciones de (r)-2-amino-3-fenilpropil carbamato.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
EP3325080A4 (en) METHOD FOR BETTER ADMINISTRATION OF AGENTS AGAINST TUMORS
BR112017004393A2 (pt) formulações de anticorpo
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
MX2015010829A (es) Compuestos terapeuticos y sus usos.
CL2016003283A1 (es) Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación
EP3538219A4 (en) TOPICAL COMPOSITION FOR TREATING ACNE
EA201790315A1 (ru) Модуляторы x-рецепторов печени
MX376029B (es) Compuestos de isoindol.
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
EP3564218A4 (en) METHOD FOR PRODUCING 1,4,7,10-TETRAAZACYCLODODECAN-1,4,7,10-TETRAIC ACID
MA43971A (fr) Formulation d'engrais granulaire capable d'augmenter la capacité de rétention d'eau du sol, procédé de préparation associé et utilisations associées
MX377257B (es) Gránulos de monensina dispersables en agua por granulación húmeda.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
EP3613750A4 (en) OPTICALLY ACTIVE 2-AMINO-PHOSPHONOALCANIC ACID, OPTICALLY ACTIVE 2-AMINO-PHOSPHONOALCANIC ACID SALT AND HYDRATES THEREOF

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ELANCO US INC.

FG Grant or registration